Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia
详细信息 查看全文
- 作者：Gabriele Gugliotta ; Fausto Castagnetti ; Massimo Breccia ; Antonella Gozzini ; Emilio Usala ; Angelo M. Carella ; Giovanna Rege-Cambrin ; Bruno Martino ; Elisabetta Abruzzese ; Francesco Albano ; Fabio Stagno ; Luigia Luciano ; Mariella D' ; Adda ; Monica Bocchia ; Francesco Cavazzini ; Mario Tiribelli ; Monia Lunghi ; Antonietta Pia Falcone ; Caterina Musolino ; Luciano Levato ; Claudia Venturi ; Simona Soverini ; Michele Cavo ; Giuliana Alimena ; Fabrizio Pane ; Giovanni Martinelli ; Giuseppe Saglio ; Gianantonio Rosti ; Michele Baccarani and on behalf of the GIMEMA CML Working Party
- 刊名：American Journal of Hematology
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：91
- 期：6
- 页码：617-622
- 全文大小：438K
- ISSN：1096-8652
文摘
The introduction of second-generation tyrosine-kinase inhibitors (TKIs) has generated a lively debate on the choice of first-line TKI in chronic phase, chronic myeloid leukemia (CML). Despite the TKIs have different efficacy and toxicity profiles, the planned use of two TKIs has never been investigated. We report on a phase 2 study that was designed to evaluate efficacy and safety of a treatment alternating nilotinib and imatinib, in newly diagnosed BCR-ABL1 positive, chronic phase, CML patients. One hundred twenty-three patients were enrolled. Median age was 56 years. The probabilities of achieving a complete cytogenetic response, a major molecular response, and a deep molecular response (MR 4.0) by 2 years were 93%, 87%, and 61%, respectively. The 5-year overall survival and progression-free survival were 89%. Response rates and survival are in the range of those reported with nilotinib alone. Moreover, we observed a relatively low rate of cardiovascular adverse events (5%). These data show that the different efficacy and toxicity profiles of TKIs could be favorably exploited by alternating their use. Am. J. Hematol. 91:617–622, 2016.